Stephanie Davis
Stock Analyst at Barclays
(0.87)
# 3,914
Out of 4,993 analysts
95
Total ratings
36.76%
Success rate
-108.34%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Equal-Weight | $175 → $185 | $185.32 | -0.17% | 5 | Apr 23, 2025 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $37.14 | +21.16% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $18.21 | -72.54% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $73.69 | +1.78% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $5.22 | +34.23% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $3.93 | +52.87% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $8.99 | +111.35% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $299.65 | -3.22% | 2 | Nov 7, 2024 | |
| PINC Premier | Maintains: Equal-Weight | $20 → $24 | $27.84 | -13.79% | 3 | Nov 6, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $149.22 | -10.87% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $39 → $58 | $30.64 | +89.30% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $2.63 | +14.07% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $276.06 | -9.80% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $23.19 | +25.05% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $8.05 | +322.36% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $21.54 | +57.85% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $278.76 | -16.42% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $2.81 | +506.06% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $96.99 | -21.64% | 5 | Jun 7, 2022 |
Quest Diagnostics
Apr 23, 2025
Maintains: Equal-Weight
Price Target: $175 → $185
Current: $185.32
Upside: -0.17%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $37.14
Upside: +21.16%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $18.21
Upside: -72.54%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $73.69
Upside: +1.78%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $5.22
Upside: +34.23%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $3.93
Upside: +52.87%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $8.99
Upside: +111.35%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $299.65
Upside: -3.22%
Premier
Nov 6, 2024
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $27.84
Upside: -13.79%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $149.22
Upside: -10.87%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $30.64
Upside: +89.30%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $2.63
Upside: +14.07%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $276.06
Upside: -9.80%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $23.19
Upside: +25.05%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $8.05
Upside: +322.36%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $21.54
Upside: +57.85%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $278.76
Upside: -16.42%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $2.81
Upside: +506.06%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $96.99
Upside: -21.64%